Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

An independent dataset of 91 multiple myeloma patients were tested with eight prognostic mRNA expression signatures. SKY92 best predicted survival (HR = 8.2) and classified the largest fraction (21%) as high risk. Finally 38/91 (42%) cases were low risk by the recently proposed combination SKY92 + ISS achieving a HR 10 for low versus high risk.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 3, 2017 Category: Hematology Authors: Erik H. van Beers, Martin H. van Vliet, Rowan Kuiper, Leonie de Best, Kenneth C. Anderson, Ajai Chari, Sundar Jagannath, Andrzej Jakubowiak, Shaji K. Kumar, Joan B. Levy, Daniel Auclair, Sagar Lonial, Donna Reece, Paul Richardson, David S. Siegel, A. Keit Tags: Original Study Source Type: research